Analysis of Jacobio Pharma Announces CNY486 Million Revenue for 2020 Annual Results - aVenture Research
PRNewswire
Jacobio Pharma Announces CNY486 Million Revenue for 2020 Annual Results
Jacobio Pharmaceuticals announced its first annual results after its Hong Kong listing: 2020 annual revenue of CNY486 million with R&D expenses exceeding CNY230 million, up 66% versus 2019, generated through licensing out its SHP2 inhibitors. The company reported clinical-stage pipelines including KRAS G12C inhibitor JAB-21000 and BET inhibitor JAB-8263, a 20,000 square meter GMP factory under construction in Beijing, and headcount growth from 130 to about 180 employees. Jacobio listed on the HKEX Main Board in December 2020, raising nearly US$200 million.
An analysis reads this article and its sources, then explains what happened, who is involved, and what it means, quoting a source for each claim. Once written, every reader sees it here.
Analysis requires a paid plan or prepaid credits and uses your company research allowance.